Objective: In this study, we describe experiences with gemcitabine -docetaxel combination therapy as salvage treatment for Chinese patients with recurrent or refractory high-grade osteosarcoma. Methods: We retrospectively reviewed the medical records of 18 patients with recurrent or refractory high-grade osteosarcoma who had undergone gemcitabine -docetaxel combination treatment as salvage chemotherapy. Gemcitabine at 675 mg/m 2 was administered on Days 1 and 8, and docetaxel at 75 -100 mg/m 2 was administered on Day 8. The combination therapy was repeated every 3 weeks. Treatment was continued until evidence of disease progression or unacceptable toxicity. Results: The patients (ages 12 -57 years) received a total of 44 cycles of chemotherapy (median: 2 courses; range: 2-6 courses). The overall response rate was 5.6% and the disease control rate was 22.3%, with one partial response and three patients with stable disease. The median time to progression and overall survival time were 2 months (range: 2-6 months) and 8 months (range: 3 -21 months), respectively. Major severe toxicities were hematologic toxicities, including Grade 3 or 4 anemia (9.1%), leucopenia (29.5%) and thrombocytopenia (18.1%) in total cycles; mild toxicities included Grade 1 or 2 nausea and vomiting (31.8%), fatigue (38.6%) and alopecia (20.5%). There were no treatment-related deaths. Conclusions: In the current study, gemcitabine -docetaxel combination therapy at this dosage and schedule was found to be well tolerated and marginally effective, which could be considered as salvage therapy for patients with recurrent or refractory high-grade osteosarcoma.
INTRODUCTION
Osteosarcoma is the most common malignant primary bone tumor in childhood (1) . Despite significant improvements have been achieved in the overall survival of patients with high-grade osteosarcoma during the past decades, recurrent disease still occurs in 30 -40% of the patients with nonmetastatic osteosarcoma and 80% of the patients with metastatic disease at diagnosis will relapse (2 -5) . Failure of standard multimodal therapy for the osteosarcoma is associated with a very poor prognosis. Therefore, new drugs or combination therapies are needed for patients with recurrent or refractory high-grade osteosarcoma.
Gemcitabine, a nucleoside antimetabolite, is an analog of deoxycytidine which mainly inhibits DNA synthesis through interfering with DNA chain elongation and depleting deoxynucleotide stores, resulting in gemcitabine-induced cell death (6) . Docetaxel is a semisynthetic analog of paclitaxel, which promotes microtubule assembly and inhibits disassembly resulting in cell cycle arrest and apoptosis (7) . In vitro study, synergistic antitumor activity of the combination of docetaxel and gemcitabine has been observed in several different cell lines, including osteosarcoma cell lines (8, 9) .
Recently, several retrospective clinical studies had been conducted to assess the efficacy and toxicity of gemcitabine -docetaxel combination therapy for sarcomas, but the results were controversial. Moreover, pathologic histologies of included patients in the studies were diverse, including Ewing sarcoma, malignant fibrous histiocytoma, osteosarcoma, synovial sarcoma, leiomyosarcoma and undifferentiated sarcoma (10 -14) . Therefore, the role of gemcitabinedocetaxel combination therapy in refractory or recurrent high-grade osteosarcoma is still not well defined. As a result, we undertake this retrospective study to assess the efficacy and toxicity of gemcitabine -docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma. As far as we know, this is the largest retrospective study to investigate gemcitabine and docetaxel combination therapy for recurrent or refractory osteosarcoma patients.
PATIENTS AND METHODS

PATIENTS AND TREATMENT
There were totally 281 patients with histopathologically or cytologically diagnosed osteosarcoma treated at our hospital between June 2007 and March 2010. Based on the following inclusion criteria [(i) diagnosis confirmed histologically; (ii) prior treatment (completed .3 weeks before trial entry) consisted of standard high-grade osteosarcoma chemotherapy agents including doxorubicin, cisplatin, high-dose methotrexate and ifosfamide; (iii) metastatic relapsed or unresectable progressive disease (PD); (iv) patients received at least two cycles of gemcitabine and docetaxel combination therapy as salvage treatment] for the study, 18 patients were included in the present study. All of the patients received three to five cycles of adjuvant chemotherapy according to two different protocols. In Protocol 1, 13 patients received optimized combination therapy of methotrexate, cisplatin, ifosfamide and doxorubicin based on Chinese patients' physiology, which was reported by our previous study (15) . The dosage and schedule was given as followed: methotrexate at a dose of 8 -12 . The combined use of these (the) drugs was repeated every 3 weeks, and each 3-week treatment schedule was designated as one cycle. In regard to the antiemetic therapy, ondansetron plus dexamethasone were used according to the ASCO guidelines. Granulocyte colony-stimulating factor was used when patients with febrile neutropenia or Grade 4 neutropenia were judged as requiring its administration by physicianin-charge.
PATIENT ASSESSMENT
Tumor response was usually evaluated every two chemotherapy cycles by computed tomography (CT)/magnetic resonance imaging scan according to the Response Evaluation Criteria in Solid Tumors (RECST) (16) . Treatment responses were classified as (i) complete response (CR): the disappearance of all target and non-target lesions with no new lesions detected; (ii) partial response (PR): at least a 30% decrease in the disease measurement with no new lesions detected; (iii) PD: at least a 20% increase in the disease measurement or the appearance of one or more new lesions; and (iv) stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD. Targeted lesions were defined as the presence of at least one measurable lesion with a longest dimension of 20 mm with a conventional technique or 10 mm using spiral CT. The sum of the longest dimension for all target lesions was calculated and designated as the disease measurement. Non-target lesions were defined as lesions that are too small to qualify as target lesions, pleural and bone disease. The maximum toxicity was recorded for each cycle of chemotherapy according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC, version 3.0).
STATISTICAL ANALYSIS
A retrospective analysis of the therapeutic effects of gemcitabine -docetaxel as a second-line chemotherapy in recurrent or relapsed osteosarcoma in terms of response rate, progression-free survival (PFS) and overall survival (OS) was performed. An OS was measured from the start of treatment to death from any cause. A PFS was defined as a time interval from the start of treatment to progression of the disease or death from any cause. Data were presented as percentage or median plus range unless otherwise specified. The Kaplan -Meier method was used to estimate the PFS and the OS. All analyses were performed with SPSS software version 13.0(SPSS, Inc., Chicago, IL, USA).
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RESULTS
PATIENT CHARACTERISTICS
Of 281 patients diagnosed with high-grade OS at our hospital between June 2007 and March 2010, 18 patients with relapsed or refractory osteosarcoma who received gemcitabine -docetaxel chemotherapy were included. All of the included patients received surgery treatment for primary lesion, including four patients who received limb amputation. The median age of patients at inclusion was 17.5 years; 13 patients were males. Most patients had Karnofsky performance status 80 and 22.2% had metastatic disease at the initial diagnosis. After primary therapy, nine patients had lung metastasis alone, four patients had local recurrence with lung metastasis and five patients had bone metastasis with lung metastasis. Of all patients, 72.2% received adjuvant chemotherapy including methotrexate-doxorubicin-cisplatinifosfamide (MTX-ADM-CDDP-IFO) ( Table 1 ).
EFFICACY AND SAFETY
All patients received at least two cycles of gemcitabine -docetaxel combination therapy (median, two cycles per patient; range: 2 -6 cycles) and a total of 44 cycles was administered. All of 18 patients were available for tumor response evaluation. After two cycles of treatment, 11 patients changed chemotherapy regimen due to disease progression, 3 patients refused to receive more chemotherapy due to personal or economic reasons, and 1 patient received six cycles of gemcitabine -docetaxel chemotherapy. We observed no CRs, but tumor control (CR þ PR þ SD) at two cycles was observed in four patients, including one PR and three SD ( Table 2 ). The overall response rate and disease control rate were 5.6 and 22.3%, respectively (Table 3) . At the cut-off date, the median OS was 8 months (range: 3 -21 months), and the median PFS was 2 months (range: 2-6 months). We recorded no drug-related deaths. In general, chemotherapy-related adverse events were limited to Grade 1 or 2. We noted the following Grade 3 and 4 toxic effects: leucopenia 13 (29.5%), anemia 4 (9.1%), thrombocytopenia 8 (18.1%), nausea and vomiting 2 (4.5%) and fatigue 6 (13.6%). Table 3 summarizes the main side effects and all Grade 3 and 4 adverse events (Table 4) .
DISCUSSION
Patients with recurrent or refractory osteosarcoma have a very poor prognosis, and new strategies are, therefore, necessary to improve the prognosis of this subgroup of patients. In the last decades, several clinical studies had been conducted to evaluate the efficacy of the gemcitabine -docetaxel regimen in recurrent or refractory osteosarcoma. McTiernan and Whelan (17) did a Phase II study, which showed that single-agent docetaxel was inactive in patients with relapsed osteosarcoma, and Mora et al. (10) reported that the gemcitabine -docetaxel regimen showed antitumor activity against Ewing sarcoma but not osteosarcoma, while Navid et al. (18) did a retrospective study to find that gemcitabinedocetaxel combination therapy was well tolerated and showed antitumor activity in children and adolescents with recurrent or refractory osteosarcoma, with an overall response rate of 30% and a disease control rate of 40%. Based on these results, the efficacy of the gemcitabine -docetaxel combination regimen in recurrent or refractory osteosarcoma patients was controversial, partially due to a relatively small number of patients included in the trials. As a result, we took this retrospective study to investigate the efficacy and toxicity of the gemcitabine -docetaxel regimen for Chinese patients with recurrent or refractory high-grade osteosarcoma. 
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Of the 18 patients available for response evaluation in this retrospective study, we found that the overall response rate and the tumor control rate for relapsing or refractory osteosarcoma were 5.6 and 22.3%, respectively. Only one patient achieved PR with a response duration of 16 weeks, and three patients who achieved SD were all died from disease progression. Thus, patients achieved benefits from the combination regimen in the current study was small compared with the efficacy reported by Navid et al. (18) . Several reasons might interpret the discrepancy of the two studies: first, dosages of gemcitabine and docetaxel in the current study were lower than those used previously in adult patients with bone and soft tissue sarcoma, gemcitabine was given at a dose of 675 mg/m 2 which was in the lowest range and the dose of docetaxel was also lower than that reported in other 430 Gemcitabine -docetaxel as salvage therapy for osteosarcoma studies; second, a possible patient selection bias might affect treatment results because of a small number of patients included in both studies; lastly, 50% of the patients in our study had a local and distant failure after primary therapy, which was higher than 19% of the patients in Navid's study. Therefore, histotypes of osteosarcoma in our study might be more aggressive and resistant to chemotherapy. At the cut-off date, six patients had died, the median OS was 8 months [95% confidence interval (CI): 3 -21 months] and the median PFS was 2 months (95% CI: 2 -6 months), which confirmed the poor prognosis of patients with recurrent or refractory osteosarcoma. Similar to what had been observed in other studies; the main adverse events of gemcitabine and docetaxel combination therapy were myelosuppression, but the incidence rates of Grade III and IV myelosuppression in our study were lower than those reported by other studies, which also partially due to the low dose of drugs. The Grade III and IV gastrointestinal disorders and myelosuppression including anemia, leucopenia and thrombocytopenia were tolerable by using 5-hydroxytryptamine-3 receptor blockers receptor blockers (as anti-emetics), adequate hydration and steroids (to relieve gastrointestinal disorders) and supportive treatments such as granulocyte colony-stimulating factor, interleukin-11 and low-dose steroids to help in recovery from myelosuppression.
The current study was limited by its retrospective nature, the small number of patients and possible patient selection bias. In addition, the staging and timing of imaging evaluations were not uniform in our patient population. However, we conducted this study to explore a completely different strategy in a rare sarcoma for which there were no other therapeutic options, though the combination therapy showed marginally effective for relapsed or refractory high-grade osteosarcoma.
In conclusion, gemcitabine in combination with docetaxel therapy at this dosage and schedule was found to be well tolerated and marginally effective in patients with recurrent or refractory high-grade osteosarcoma. We recommended more aggressive and higher dosages of gemcitabine and docetaxel for recurrent or refractory osteosarcoma patients based on our single-institute experience, but the suggestions needed to be confirmed in large retrospective or prospective studies.
